Microbix antigens are at the core of the world’s leading infectious disease assays. Proficiency programs trust our samples to assess the reliability and performance of clinical laboratory tests. Our expertise in cell biology is reflected in LumiSort, an animal reproductive product and Kinlytic, a biopharmaceutical used to treat blood clots.

medical-home

INFECTIOUS DISEASE ANTIGENS

See our expanding menu of antigens here.

cows-home

LUMISORT™ TECHNOLOGY

Find out more about the revolutionary technology here.

virus-home

MOLECULAR DIAGNOSTICS

See Microbix’ products for this emerging market.

blood-home

KINLYTIC™

Learn about this thrombolytic drug here.

Latest from the Newsroom

  • Microbix Appoints New Chief Financial Officer

    TORONTO November 1, 2016 — Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today announced that Charles Wallace, the Company’s Chief Financial Officer, is retiring on December 31, 2016 after serving in this capacity since September 2013. Microbix also announced that......

  • Join us at Medica in Dusseldorf, Germany from November 14 – 17, 2016. Hall 3 Booth H14

    Medica is the world’s leading trade fair for the medical industry. The trade fair is a concentration of our existing and potential industry partners and we invite you to drop by our booth. If you would like to schedule time with a technical or sales......

  • MICROBIX ANNOUNCES PRELIMINARY SALES FOR 2016 – Record Sales for Fourth Quarter and Full Year

    TORONTO, October 19, 2016 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today announced preliminary revenue results (unaudited) for its fourth quarter and full year ending September 30, 2016. The preliminary results are subject to the Company’s annual audit including......